Page results
-
Acute loss of sense of smell should be considered globally as a criterion for self-isolation, testing, and contact tracing for Covid-19 infection according to researchers at UCLH and UCL.
-
This page is for patients who have been referred by their GP to a gynaecology specialist because their symptoms need further tests.
-
A research team involving UCLH clinicians has found a way to reduce the side effects of treatment for a disorder of the adrenal glands.
-
UCLH NHS Foundation Trust has once again formed a partnership with the Business Design Centre in Islington to reopen a large-scale COVID-19 vaccination centre on site from Saturday 18 December.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
This page is for patients who have been referred on a suspected cancer pathway.
-
This page has been written for parents, carers and family members who are acting as carers and comforters for children and young people having radioactive mIBG treatment.
File results
-
FOI/2023/0304 - Chronic lymphocytic leukaemia treatments
-
FOI/2023/0308 - Treatment for biologic and biosimilar products within rheumatology
-
FOI/2023/0310 - Biologic treatment/ medicines in dermatology
-
FOI/2023/0313 - Consent, confidentiality and information sharing in mental healthcare and suicide
-
FOI/2023/0315 - Menopause Lead at the Trust
-
FOI/2023/0319 - Multiple Sclerosis (MS) treatment/ medication for any diseases
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine
-
FOI/2023/0326 - Risk management system reporting rates for adverse events
-
FOI/2023/0327 - NHS long-term plan/ prevention strategy
-
FOI/2023/0330 - Outsourced/ in-house occupational health provisions